Science ❯ Biotechnology ❯ Drug Development

Clinical Research

Phase 3 Trials Gene Therapy Cancer Treatment Therapeutic Proteins Phase 1 Trials Therapeutic Effects AI Applications in Medicine FDA-Approved Drugs Midstage Trials Innovations Biomarker Testing Innovative Therapies Seizure Medications Regulatory Affairs Oncology

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Amylyx plans a year‑end FDA filing that could lead to a 2027 launch funded by a new equity offering.

Takeda Signs $600 Million‑Value AI Drug Discovery Deal With Insilico

Altimmune Targets Second-Half 2026 Launch for Global Phase 3 MASH Trial

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

myTomorrows Raises $29 Million From Avego to Scale AI Platform for Pre-Approval Treatments

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research